Page 193 - Haematologica March 2020

Targeting BCL2 and MAPK in AML
2013;12(3):329-341.
5. Carter BZ, Mak PY, Mu H, et al. Combined
targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8(355): 355ra117.
6. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21 (2):178-184.
7. Goff DJ, Court Recart A, Sadarangani A, et al. A pan-BCL2 inhibitor renders bone-mar- row-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12(3):316-328.
8. Saito Y, Mochizuki Y, Ogahara I, et al. Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. Sci Transl Med. 2017;9(413).
9. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-tar- get cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362-375.
10. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monother- apy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106- 1117.
11. Konopleva M, Milella M, Ruvolo P, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modu- lation of MCL-1/BIM complex. Leukemia. 2012;26(4):778-787.
12. Lin KH, Winter PS, Xie A, et al. Targeting MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 2016;6:27696.
13. Lauchle JO, Kim D, Le DT, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009;461(7262):411-414.
14. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013;313-318.
15. Jain N, Curran E, Iyengar NM, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014;20(2):490-498.
16. Yeh YY, Chen R, Hessler J, et al. Up-regula- tion of CDK9 kinase activity and Mcl-1 sta- bility contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget. 2015;6(5):2667-2679.
17. Pei XY, Dai Y, Tenorio S, et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood. 2007; 110(6):2092-2101.
18. Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732-741.
19. Zhang Q, Han L, Shi C, et al. Upregulation of MAPK/MCL-1 maintaining mitochondrial oxidative phosphorylation confers acquired resistance to BCL-2 inhibitor venetoclax in AML. Blood. 2016; 128(22):101-101.
20. Hatzivassiliou G, Haling JR, Chen H, et al.
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-dri- ven cancers. Nature. 2013;501(7466):232- 236.
21. Hirashita Y, Tsukamoto Y, Yanagihara K, et al. Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells. Cancer Sci. 2016;107(12):1919-1928.
36. Ricciardi MR, Scerpa MC, Bergamo P, et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strate- gies. J Mol Med (Berl). 2012;90(10):1133- 1144.
37. Airiau K, Prouzet-Mauleon V, Rousseau B, et al. Synergistic cooperation between ABT- 263 and MEK1/2 inhibitor: effect on apopto- sis and proliferation of acute myeloid leukemia cells. Oncotarget. 2016;7(1):845-
22. Corcoran RB, Rothenberg SM, Hata AN, et
al. TORC1 suppression predicts responsive-
ness to RAF and MEK inhibition in BRAF- 859.
mutant melanoma. Sci Transl Med.
2013;5(196):196ra198.
23. Teh JLF, Cheng PF, Purwin TJ, et al. In vivo
E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR- S6 resistance mechanisms. Cancer Discov. 2018;8(5):568-581.
24. Pabst C, Krosl J, Fares I, et al. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat Methods. 2014;11(4):436-442.
25. Chou TC. Drug combination studies and their synergy quantification using the Chou- Talalay method. Cancer Res. 2010;70(2): 440-446.
26. Han L, Qiu P, Zeng Z, et al. Single-cell mass cytometry reveals intracellular survival/pro- liferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015;87(4):346-356.
27. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118(2): 217-228.
28. Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34(17):2239-2250.
29. Croft A, Tay KH, Boyd SC, et al. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticu- lum stress. J Invest Dermatol. 2014;134(2): 488-497.
30. Yoshino S, Hara T, Nakaoka HJ, et al. The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux. Cell Discov. 2016;2:16019.
31. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoi- etic stem cells in acute leukaemia. Nature. 2014;506(7488):328-333.
32. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
33. Burgess MR, Hwang E, Firestone AJ, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014;124(26): 3947-3955.
34. Borthakur G, Popplewell L, Boyiadzis M, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122(12):1871- 1879.
35. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375-388.
38. Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013;23(1):121-128.
39. Bendall SC, Simonds EF, Qiu P, et al. Single- cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011; 332(6030):687-696.
40. Fisher DAC, Malkova O, Engle EK, et al. Mass cytometry analysis reveals hyperactive NF kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017;31(9):1962-1974.
41. Levine JH, Simonds EF, Bendall SC, et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell. 2015;162(1):184-197.
42. Qiu P, Simonds EF, Bendall SC, et al. Extracting a cellular hierarchy from high- dimensional cytometry data with SPADE. Nat Biotechnol. 2011;29(10):886-891.
43. Roux PP, Shahbazian D, Vu H, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007;282(19):14056-14064.
44. Sale MJ, Cook SJ. The BH3 mimetic ABT- 263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM- dependent tumour cell death and inhibit acquired resistance. Biochem J. 2013;450(2): 285-294.
45. Pan R, Ruvolo V, Mu H, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32(6):748-760.
46. Tsai WB, Aiba I, Long Y, et al. Activation of Ras/PI3K/ERK pathway induces c-Myc sta- bilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 2012;72(10):2622-2633.
47. Serasinghe MN, Gelles JD, Li K, et al. Dual suppression of inner and outer mitochondr- ial membrane functions augments apoptotic responses to oncogenic MAPK inhibition. Cell Death Dis. 2018;9(2):29.
48. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour devel- opment: friend or foe? Nat Rev Cancer. 2004;4(12):966-977.
49. Daver N, Pollyea DA, Yee KWL, et al. Preliminary results from a phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobime- tinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R/R) AML. Blood. 2017;130 (Suppl 1):813.
haematologica | 2020; 105(3)
707